Clinical Trial Update: Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) [Phase 3]

View source ↗

Summary

Phase 3 study comparing AVT06 with EU-Eylea (ALVOEYE) for neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• ALVOEYE (aflibercept)
• AVT06 (aflibercept)

Snippet

Sponsor: Alvotech Swiss AG | Conditions: Neovascular (Wet) AMD | Phase 3 | Status: COMPLETED